These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Kacar A; Bjelica B; Bozovic I; Peric S; Nikolic A; Cobeljic M; Petrovic M; Stojanov A; Djordjevic G; Vukojevic Z; Dominovic-Kovacevic A; Stojanovic M; Stevic Z; Rakocevic-Stojanovic V; Lavrnic D; Basta I J Peripher Nerv Syst; 2018 Mar; 23(1):11-16. PubMed ID: 29360221 [TBL] [Abstract][Full Text] [Related]
26. Impact of social-functioning and sleep on quality of life in chronic inflammatory demyelinating polyneuropathy. Englezou C; Nazeer KK; Rajabally YA Clin Neurol Neurosurg; 2023 Nov; 234():108017. PubMed ID: 37866209 [TBL] [Abstract][Full Text] [Related]
27. Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy. Lucke IM; Wieske L; van der Kooi AJ; van Schaik IN; Eftimov F; Verhamme C J Peripher Nerv Syst; 2019 Jun; 24(2):174-179. PubMed ID: 31090121 [TBL] [Abstract][Full Text] [Related]
28. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. Mengel D; Fraune L; Sommer N; Stettner M; Reese JP; Dams J; Glynn RJ; Balzer-Geldsetzer M; Dodel R; Tackenberg B Muscle Nerve; 2018 Nov; 58(5):681-687. PubMed ID: 30073683 [TBL] [Abstract][Full Text] [Related]
30. Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins. Lawley A; Seri S; Rajabally YA Clin Neurophysiol; 2019 Oct; 130(10):1743-1749. PubMed ID: 31400577 [TBL] [Abstract][Full Text] [Related]
31. Demyelinating findings in typical and atypical chronic inflammatory demyelinating polyneuropathy: sensitivity and specificity. De Sousa EA; Chin RL; Sander HW; Latov N; Brannagan TH J Clin Neuromuscul Dis; 2009 Jun; 10(4):163-9. PubMed ID: 19494726 [TBL] [Abstract][Full Text] [Related]
33. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin. Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110 [TBL] [Abstract][Full Text] [Related]
34. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Caro XJ; Winter EF; Dumas AJ Rheumatology (Oxford); 2008 Feb; 47(2):208-11. PubMed ID: 18208823 [TBL] [Abstract][Full Text] [Related]
35. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. Nasu S; Misawa S; Sekiguchi Y; Shibuya K; Kanai K; Fujimaki Y; Ohmori S; Mitsuma S; Koga S; Kuwabara S J Neurol Neurosurg Psychiatry; 2012 May; 83(5):476-9. PubMed ID: 22338030 [TBL] [Abstract][Full Text] [Related]
36. Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin. Markvardsen LH; Vaeggemose M; Ringgaard S; Andersen H Neuroradiology; 2016 Aug; 58(8):745-52. PubMed ID: 27114080 [TBL] [Abstract][Full Text] [Related]
37. Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients. Dorst J; Ludolph AC; Senel M; Tumani H J Neurol; 2018 Dec; 265(12):2906-2915. PubMed ID: 30293110 [TBL] [Abstract][Full Text] [Related]